^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    1d
    TALMMY1001-PT3: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=510, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> Jun 2027
    Trial primary completion date • First-in-human
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs)
    1d
    SILVERGLO: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1d
    MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=166, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Oct 2027
    Trial completion date
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
    2d
    DeLLphi-313: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=160, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    2d
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=21, Completed, Boehringer Ingelheim | N=97 --> 21 | Trial completion date: Sep 2028 --> Oct 2025 | Trial primary completion date: Jun 2028 --> Aug 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    2d
    A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (clinicaltrials.gov)
    P2, N=220, Recruiting, Amgen | Trial completion date: Mar 2029 --> Jul 2028 | Trial primary completion date: Jan 2028 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    Blincyto (blinatumomab) • Uplizna (inebilizumab-cdon)
    3d
    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, University of Alberta | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    CD19 positive
    |
    clonoSEQ
    |
    Iclusig (ponatinib)
    3d
    A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=101, Not yet recruiting, Sinocelltech Ltd.
    New P3 trial
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin
    3d
    MDX-2001-101: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=285, Recruiting, ModeX Therapeutics, An OPKO Health Company | N=115 --> 285
    Enrollment change • First-in-human
    3d
    CLEAR-AbKD: A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease (clinicaltrials.gov)
    P2, N=43, Recruiting, AstraZeneca
    New P2 trial
    |
    surovatamig (AZD0486)
    3d
    CLN-978-RA-101: A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) (2024-519114-31-00)
    P1, N=46, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    3d
    CLN-978-RA-101: A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) (2024-519114-31-00)
    P1, N=46, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLN-978